Mutagenicity Assessment for Medical Devices: Standards, Testing Strategy, and Regulatory Compliance

Mutagenicity assessment is a critical component of the biological evaluation of medical devices, verifying that device materials, extractables, and leachables do not induce heritable damage to DNA. Performed in accordance with ISO 10993-3 and OECD test guidelines, this evaluation combines chemical characterization with in vitro and in vivo genotoxicity testing to support regulatory submissions worldwide. This article outlines the standards, sample preparation requirements, core test items, methodologies, and practical considerations for a compliant mutagenicity evaluation program.

Technical Overview

Mutagenicity refers to the capacity of a chemical or material to induce permanent, transmissible changes in the sequence or structure of DNA in somatic or germ cells. Because DNA damage is closely associated with carcinogenesis, reproductive toxicity, and heritable disease, mutagenicity assessment is a mandatory endpoint within the biological evaluation framework for medical devices under the ISO 10993 series of standards.

The governing standard is ISO 10993-3, Biological evaluation of medical devices — Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity, which is applied together with ISO 10993-1 (evaluation and testing within a risk management process), ISO 10993-12 (sample preparation and reference materials), ISO 10993-17 (toxicological risk assessment), and ISO 10993-18 (chemical characterization of medical device materials). Modern ISO 10993-3:2014, including its 2020 amendment, promotes a step-wise, science-based strategy:

• Step 1 — Chemical characterization and toxicological risk assessment: device extracts are analytically screened (GC-MS, LC-MS, ICP-MS) to identify extractables and leachables, and each compound is evaluated against toxicological reference data or Threshold of Toxicological Concern (TTC) values derived from the ICH M7 framework for mutagenic impurities.
• Step 2 — In vitro genotoxicity battery: if risks cannot be ruled out analytically, a minimum of two complementary in vitro assays are performed — one detecting gene mutations and one detecting chromosomal damage.
• Step 3 — In vivo testing: only justified when Step 2 results are positive or when in vitro data are insufficient for risk conclusion.

This tiered approach minimizes unnecessary animal testing while ensuring that patient-contacting devices — particularly those with prolonged or permanent contact, absorbable materials, or significant processing residuals — do not expose patients to genotoxic hazards.

Testing Samples

Device Extracts

Testing is typically performed on device extracts rather than the intact device, prepared according to ISO 10993-12. A standard polar/non-polar extraction pair is used:

• Polar vehicles: physiological saline (0.9% NaCl) or cell culture medium with serum — suitable for the bacterial reverse mutation test and mammalian cell assays.
• Non-polar vehicles: sesame oil or similar oils — primarily for cytotoxicity-adjacent screening; dimethyl sulfoxide (DMSO) or ethanol/water mixtures may serve as vehicles when analytically justified.

Extraction Ratios

• For regular-shaped surfaces: 3 cm² of surface area per mL of extraction vehicle (thin materials) or 1.25 cm²/mL (thick materials above approximately 0.5 mm).
• For irregular, porous, or absorbent materials: 0.1 g to 0.2 g of material per mL of vehicle.
• For hollow devices and fluid pathways: the volume of fluid that contacts the device in clinical use.

Extraction Conditions

Standard conditions include 37 °C for 24 hours (simulating clinical use), 50 °C for 72 hours, 70 °C for 24 hours, or 121 °C for 1 hour. The selected condition should be as rigorous as possible without degrading the material or generating artificial degradation artifacts.

Device Categories Covered

• Surface-contacting devices (skin, mucous membranes, breached or compromised surfaces).
• External communicating devices (indirect blood path, tissue/bone/dentin contact, circulating blood contact).
• Implantable devices (tissue/bone contact, blood contact).
• Absorbable and biodegradable devices, drug-device combination products, and devices with significant sterilization or manufacturing residuals (e.g., ethylene oxide, curing agents, monomers, plasticizers, colorants).

Testing Items

A mutagenicity and genotoxicity evaluation program for medical devices generally includes the following endpoints:

• Bacterial reverse mutation test (Ames test): detects point mutations (frameshift and base-pair substitution) — the primary gene mutation assay.
• In vitro mammalian chromosomal aberration test: detects structural and numerical chromosome damage in mammalian cells.
• In vitro micronucleus test: an accepted alternative for detecting chromosome breakage and whole-chromosome loss.
• In vitro mammalian cell gene mutation test (e.g., mouse lymphoma assay, HPRT/XPRT assay): quantifies forward gene mutations in mammalian cells.
• In vivo rodent micronucleus test: evaluates chromosomal damage in bone marrow or peripheral blood erythrocytes when in vitro follow-up is required.
• In vivo comet assay: detects primary DNA strand breaks in target tissues, useful for site-of-contact tissues.
• Chemical characterization and TTC-based risk assessment: identification and toxicological evaluation of extractables, leachables, degradation products, and residuals per ISO 10993-18 and ISO 10993-17.

Testing Methods

Bacterial Reverse Mutation Test (OECD TG 471)

The Ames test is conducted with the standard strain panel of Salmonella typhimurium TA1535, TA1537, TA98, and TA100, plus Escherichia coli WP2 uvrA (or WP2 uvrA pKM101) to broaden the spectrum of detectible mutations. Testing is performed both with and without an exogenous metabolic activation system (S9 mix prepared from Aroclor- or phenobarbital/β-naphthoflavone-induced rat liver). Both the plate incorporation and pre-incubation procedures may be applied; the pre-incubation method is preferred for extracts containing potentially volatile or poorly diffusing substances. Positive controls such as sodium azide, 4-nitroquinoline-N-oxide, ICR-191, mitomycin C, and 2-aminoanthracene validate strain sensitivity and S9 activity. Results are assessed by revertant colony counts relative to vehicle controls; a reproducible, dose-related increase of at least twofold (strains TA1535/TA1537) or 1.5-fold to 2-fold (other strains) indicates a positive response.

In Vitro Mammalian Chromosomal Aberration Test (OECD TG 473)

Chinese hamster ovary (CHO) or lung (CHL) cells, or human peripheral lymphocytes, are exposed to device extracts in short-term (3–6 hours with and without S9) and extended (20–24 hours without S9) treatment regimens. Cytotoxicity is characterized by mitotic index, relative population doubling, or replication index, with the top concentration targeting approximately 50% cytotoxicity or maximum soluble/achievable concentration. At least 300 well-spread metaphases per concentration are scored for chromatid- and chromosome-type aberrations, including gaps, breaks, exchanges, and pulverization.

In Vitro Mammalian Cell Gene Mutation Test (OECD TG 476)

The mouse lymphoma L5178Y TK^+/- assay or the HPRT/XPRT assay using CHO cells quantifies forward mutations at the thymidine kinase or hypoxanthine-guanine phosphoribosyltransferase loci. Mutant frequency is compared against concurrent vehicle controls after an expression period and selective cloning with trifluorothymidine or 6-thioguanine. The mouse lymphoma assay additionally detects large chromosomal deletions and recombination, making it uniquely sensitive to both point mutagens and clastogens.

In Vitro Micronucleus Test (OECD TG 487)

Human lymphocytes or rodent cell lines are treated with extracts using cytokinesis-block methodology (cytochalasin B) or absolute counting, and at least 2,000 binucleated or mononucleated cells per concentration are examined for micronuclei. Cytostasis is measured via the cytokinesis-block proliferation index or replication index to ensure testing occurred at appropriate cytotoxicity levels.

In Vivo Follow-Up Tests (OECD TG 474 and TG 489)

When in vitro results require confirmation, the rodent bone marrow micronucleus test (OECD TG 474) evaluates chromosomal damage in hematopoietic cells after acute dosing, and the comet assay (OECD TG 489) measures DNA strand breaks in site-of-contact or systemic tissues. Study designs incorporate dose-range findings, concurrent positive controls (e.g., cyclophosphamide, ethyl methanesulfonate), and animal welfare principles consistent with the 3Rs.

Quality and Compliance

All assays should be conducted in GLP-compliant facilities at accredited third-party laboratories, with documented test article characterization, vehicle and sterility controls, and acceptance criteria met for each assay. Final interpretation must integrate chemical characterization data and be documented within the biological evaluation file required by ISO 10993-1 and the overall risk management process of ISO 14971.

Applications

• Regulatory submissions: technical documentation for EU MDR CE marking, US FDA 510(k) and PMA applications, China NMPA device registration, and Japan PMDA approvals, where genotoxicity is a required endpoint for contact categories with cumulative exposure beyond 24 hours.
• New material and supplier qualification: demonstrating the genotoxic safety of novel polymers, alloys, coatings, adhesives, and bioresorbable materials.
• Sterilization and process validation: evaluation of ethylene oxide residues, radiation-induced degradation products, and cleaning or sterilant residuals.
• Change control: re-evaluation following material, manufacturing site, sterilization method, or packaging changes.
• Extractables and leachables programs: supporting toxicological risk assessments for infusion sets, dialyzers, syringes, catheters, implantables, and drug-device combination products.
• Literature-gap resolution: filling data gaps when existing toxicological literature is insufficient to conclude safety for the specific clinical exposure scenario.

FAQ

When is mutagenicity testing required for a medical device?

ISO 10993-1 requires genotoxicity evaluation for devices with contact durations categorized as prolonged (24 hours to 30 days) or permanent (beyond 30 days), as well as for any device where materials or manufacturing residuals lack adequate toxicological data. Short-term contact devices may be exempt if chemical characterization demonstrates acceptable risk.

Can chemical characterization replace biological mutagenicity testing?

Yes, in many cases. If all extractables and leachables are identified, quantified, and shown by toxicological risk assessment (including TTC thresholds such as 1.5 µg/day for cohorts of concern per ICH M7-aligned approaches) to present negligible risk, in vitro testing may be waived with scientific justification documented in the biological evaluation file.

Why are two in vitro tests required?

No single assay detects all classes of DNA damage. A battery pairing a gene mutation endpoint (Ames test or mammalian gene mutation assay) with a chromosomal damage endpoint (chromosomal aberration or micronucleus test) provides complementary coverage of point mutations and structural chromosomal effects, consistent with ISO 10993-3 requirements.

What happens if an in vitro test is positive?

A positive in vitro result does not automatically mean the device is unsafe. A weight-of-evidence review follows, including confirmation testing and, where justified, an appropriate in vivo assay. If the genotoxic hazard is confirmed, risk mitigation such as material substitution, process optimization, or extraction reduction is implemented.

How are extraction vehicles selected for the Ames test?

Physiological saline and DMSO are the most common vehicles for bacterial mutagenicity testing because they are compatible with the test system. The vehicle must be non-toxic to the test organisms, not interfere with metabolic activation, and permit maximum extraction of potential mutagens from the device.

What is the typical turnaround time?

A standard two-assay in vitro battery with sample preparation typically requires approximately 6 to 10 weeks from receipt of samples to final report, while programs including chemical characterization or in vivo follow-up may require 3 to 6 months depending on analytical complexity and study design.